|Table of Contents|

The inhibition against GIST-T1 cells by gleevec combing with simvastatin

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2014 01
Page:
15-0018
Research Field:
Publishing date:

Info

Title:
The inhibition against GIST-T1 cells by gleevec combing with simvastatin
Author(s):
Cheng Yao; Diao Dongmei; Zhang Hao; Guo Qi; Wu Xuandi; Liu Di; Zhao Shuo; Dang Chengxue
Department of Surgical Oncology,First Affiliated Hosptial of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
gastrointestinal stromal tumor (GIST); gleevec; simvastatin
PACS:
R73-36+2；R735
DOI:
10.3969/j.issn.1672-4992.2014.01.05
Abstract:
Objective:Gastrointestinal stromal tumor (GIST) is a common digestive cancer which resists common chemotherapy and radiotherapy,and has a poor prognosis.Gleevec is the only chemotherapy agent which is able to inhibit GIST.It is important to search for agents that accompany with gleevec to get more efficiency in the therapy of GIST.Methods:We use simvastatin combing with gleevec,wondering whether simvastatin was able to enhance the cytotoxic effect against GIST cell GIST-T1 in vitro,searching for new idea of therapy way to cure or alleviate GIST progression.Cell viability was performed by MTT detect,and Western blot were performed to detect apoptosis and activation of signaling.Results:Cell viability result showed that simvastatin can inhibit the proliferation of GIST-T1 cell,combing with gleevec,simvastatin increased the growth inhibition effect in virto via activating caspase-3 mediated apoptosis.By using JNK inhibitor SP600125 alleviated simvastatin induced apoptosis and cleaved-caspase-3.Conclusion:Simvastatin enhance the cytotoxic effect of gleevec therapy in vitro by up-regulation of JNK-MAPK signaling mediated apoptosis,which may be a potential way of treatment on GIST.

References:

［1］Italiano A,Cioffi A,Coco P,et al.Patterns of care,prognosis,and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib［J］.Ann Surg Oncol,2012,19(5):1551-1559.
［2］Kanda T,Ishikawa T,Hirota S,et al.Prospective observational study of imatinib therapy in Japanese patients with advanced gastrointestinal stromal tumors:long-term follow-up and second malignancy［J］.Jpn J Clin Oncol,2012,42(7):578-585.
［3］Bhanvadia VM,Trivedi B,Sheikh SS,et al.CD117 (C-Kit)-negative jejunal epithelioid gastrointestinal stromal tumour (GIST) presenting as intussusception［J］.J Gastrointest Cancer,2012,43(suppl 1):S97-S100.
［4］Pantaleo MA,Nicoletti G,Nanni C,et al.Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET［J］.J Exp Clin Cancer Res,2010,29:173.
［5］Gulati AP,Saif MW.Retinal neovascularization and hemorrhage associated with the use of imatinib ［Gleevec(R)］in a patient being treated for gastrointestinal stromal tumor (GIST)［J］.Anticancer Res,2012,32(4):1375-1377.
［6］Schmidt C.FDA updates Gleevec label for GIST patients［J］.J Natl Cancer Inst,2012,104(5):346.
［7］Yoo C,Ryu MH,Ryoo BY,et al.Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors:correlation between changes in covariates and imatinib exposure［J］.Invest New Drugs,2012,30(4):1703-1708.
［8］Rossi F,Ehlers I,Agosti V,et al.Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor［J］.Proc Natl Acad Sci USA,2006,103(34):12843-12848.
［9］Heinrich MC,Corless CL,Blanke CD,et al.Molecular correlates of imatinib resistance in gastrointestinal stromal tumors［J］.J Clin Oncol,2006,24(29):4764-4774.
［10］Antonescu CR,Besmer P,Guo T,et al.Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation［J］.Clin Cancer Res,2005,11(11):4182-4190.
［11］Fang Z,Tang Y,Fang J,et al.Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR,ERK and JAK2/STAT3 pathway［J］.PLoS One,2013,8(5):e62823.
［12］Pidhorecky I,Cheney RT,Kraybill WG,et al.Gastrointestinal stromal tumors:current diagnosis,biologic behavior,and management［J］.Ann Surg Oncol,2000,7(9):705-712.
［13］Ryu MH,Kang WK,Bang YJ,et al.A prospective,multicenter,phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor［J］.Oncology,2009,76(5):326-332.
［14］Hwang KE,Park C,Kwon SJ,et al.Synergistic induction of apoptosis by sulindac and simvastatin in A549 human lung cancer cells via reactive oxygen species-dependent mitochondrial dysfunction［J］.Int J Oncol,2013,43(1):262-270.
［15］Han JY,Lim KY,Yu SY,et al.A phase 2 study of irinotecan,cisplatin,and simvastatin for untreated extensive-disease small cell lung cancer［J］.Cancer,2011,117(10):2178-2185.

Memo

Memo:
国家自然科学基金资助项目（编号：30973489）
Last Update: 2013-12-03